Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $2.1 million.

  • Lifecore Biomedical, Inc. \De\'s Capital Expenditures fell 2270.55% to $2.1 million in Q2 2025 from the same period last year, while for May 2025 it was $13.4 million, marking a year-over-year decrease of 2707.26%. This contributed to the annual value of $13.4 million for FY2025, which is 2707.26% down from last year.
  • Latest data reveals that Lifecore Biomedical, Inc. \De\ reported Capital Expenditures of $2.1 million as of Q2 2025, which was down 2270.55% from $5.5 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Capital Expenditures registered a high of $13.1 million during Q2 2021, and its lowest value of $2.1 million during Q2 2025.
  • Moreover, its 5-year median value for Capital Expenditures was $5.2 million (2021), whereas its average is $5.6 million.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Capital Expenditures skyrocketed by 18577.06% in 2021 and then plummeted by 6217.76% in 2024.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Capital Expenditures (Quarter) stood at $5.4 million in 2021, then dropped by 29.06% to $3.8 million in 2022, then rose by 10.73% to $4.3 million in 2023, then crashed by 42.74% to $2.4 million in 2024, then decreased by 14.06% to $2.1 million in 2025.
  • Its Capital Expenditures stands at $2.1 million for Q2 2025, versus $5.5 million for Q1 2025 and $2.4 million for Q4 2024.